TCM
CLRB icon

Tradewinds Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Tradewinds Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-33
Closed -$9K – 776
2021
Q3 		$9K Hold
33
– – ﹤0.01% 478
2021
Q2 		$12K Hold
33
– – ﹤0.01% 448
2021
Q1 		$16K Buy
+33
New +$19.6K ﹤0.01% 372

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tradewinds Capital Management's CLRB Position: Q4 2021 in Review

Tradewinds Capital Management sold out of Cellectar Biosciences (CLRB) in Q4 2021, closing a stake of 33 shares — an estimated $9K sold.

Tradewinds Capital Management first reported a position in CLRB in Q1 2021 and held it in 3 quarters. The position peaked at $16K in Q1 2021. 41 funds tracked by Wall St. Rank hold CLRB as of Q4 2021.

  • Tradewinds Capital Management reported no remaining Cellectar Biosciences position as of Q4 2021 after selling out during the quarter.
  • Tradewinds Capital Management sold 33 Cellectar Biosciences shares in Q4 2021, an estimated $9K.
  • Tradewinds Capital Management first reported a position in Cellectar Biosciences in Q1 2021 and held it in 3 quarters.
  • Tradewinds Capital Management's Cellectar Biosciences position peaked at $16K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2021.

Based on Tradewinds Capital Management's 13F filing for Q4 2021, filed 2 Feb 2022.